Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Moderate Buy” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.60.

Several research analysts have commented on IRWD shares. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Craig Hallum dropped their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, JMP Securities dropped their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th.

Insider Buying and Selling

In related news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at $2,042,715.84. This trade represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 192,381 shares of company stock worth $338,591. Corporate insiders own 12.90% of the company’s stock.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Ironwood Pharmaceuticals by 6.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 286,990 shares of the biotechnology company’s stock valued at $1,271,000 after acquiring an additional 17,265 shares during the period. State of Wyoming boosted its stake in Ironwood Pharmaceuticals by 37.8% in the fourth quarter. State of Wyoming now owns 41,858 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 11,479 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $36,000. ProShare Advisors LLC boosted its stake in Ironwood Pharmaceuticals by 28.9% in the fourth quarter. ProShare Advisors LLC now owns 50,204 shares of the biotechnology company’s stock valued at $222,000 after acquiring an additional 11,267 shares during the period. Finally, Nomura Holdings Inc. acquired a new position in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $106,000.

Ironwood Pharmaceuticals Price Performance

NASDAQ:IRWD opened at $1.94 on Thursday. The business’s 50-day moving average is $3.43 and its two-hundred day moving average is $4.00. Ironwood Pharmaceuticals has a 12 month low of $1.59 and a 12 month high of $15.26. The firm has a market capitalization of $310.46 million, a PE ratio of -64.67 and a beta of 0.29.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.